Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?

This publication has 69 references indexed in Scilit:

• Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
  Journal of Hepatology, 2015
• Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial
  Gut, 2015
• Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine
  Gastroenterology, 2014
• No Detectable Resistance to Tenofovir Disoproxil Fumarate After 6 Years of Therapy in Patients With Chronic Hepatitis B
  Hepatology, 2013
• The changing pattern of epidemiology in hepatocellular carcinoma
  Digestive and Liver Disease, 2010
• Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B
  Hepatology, 2010
• Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #
  Hepatology, 2009
• Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present
  Antimicrobial Agents and Chemotherapy, 2007
• Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
  New England Journal of Medicine, 2004
• Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine
  Antimicrobial Agents and Chemotherapy, 2004